HP
WHWK

Harbourvest Partners’s Whitehawk Therapeutics WHWK Stock Holding History

Harbourvest Partners’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,647
Closed -$246K – 39
2018
Q4 		$246K Buy
+9,647
New +$307K 0.12% 28

Other funds holding WHWK

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Harbourvest Partners's WHWK Position: Q1 2019 in Review

Harbourvest Partners sold out of Whitehawk Therapeutics (WHWK) in Q1 2019, closing a stake of 9,647 shares — an estimated $246K sold.

Harbourvest Partners first reported a position in WHWK in Q4 2018 and held it in 1 quarter. The position peaked at $246K in Q4 2018. 25 funds tracked by Wall St. Rank hold WHWK as of Q1 2019.

  • Harbourvest Partners reported no remaining Whitehawk Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Harbourvest Partners sold 9,647 Whitehawk Therapeutics shares in Q1 2019, an estimated $246K.
  • Harbourvest Partners first reported a position in Whitehawk Therapeutics in Q4 2018 and held it in 1 quarter.
  • Harbourvest Partners's Whitehawk Therapeutics position peaked at $246K in Q4 2018.
  • 25 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2019.

Based on Harbourvest Partners's 13F filing for Q1 2019, filed 13 May 2019.